Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B L Roth

Showing results (11-20 of 111) with videos related to

Pageof 12
Sort By:
Molecular Psychiatry|August 2, 2007
The pipeline and future of drug development in schizophreniaJ A Gray, B L Roth
The American Journal of Physiology|May 1, 1987
Altered hepatic vasopressin and alpha 1-adrenergic receptors after chronic endotoxin infusionB L Roth, J A Spitzer
Journal of Neurochemistry|June 1, 1984
Microsomal opiate receptors: characterization of smooth microsomal and synaptic membrane opiate receptorsB L Roth, C J Coscia
Peptides|January 1, 1985
The postnatal development of VIP binding sites in rat forebrain and hindbrainB L Roth, M C Beinfeld
Biochemical and Biophysical Research Communications|January 29, 1986
Phorbol esters inhibit alpha 1-adrenergic receptor-stimulated phosphoinositide hydrolysis and contraction in rat aorta: evidence for a link between vascular contraction and phosphoinositide turnoverM McMillan, B Chernow, B L Roth
Circulatory Shock|January 1, 1986
Hepatic alpha 1-adrenergic receptor alteration in a rat model of chronic sepsisM McMillan, B Chernow, B L Roth
Molecular Pharmacology|October 1, 1992
Identification of receptor domains that modify ligand binding to 5-hydroxytryptamine2 and 5-hydroxytryptamine1c serotonin receptorsM S Choudhary, S Craigo, B L Roth
Brain Research|April 1, 1982
Differential postnatal development of mu and delta opiate receptorsM Wohltmann, B L Roth, C J Coscia
Advances in Pharmacology (San Diego, Calif.)|November 5, 1997
Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptorsB L Roth, H Y Meltzer, N Khan
Molecular Pharmacology|May 1, 1993
A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptorsM S Choudhary, S Craigo, B L Roth
Pageof 12

Showing results (11-20 of 111) with videos related to

Sort By:
Pageof 12
Molecular Psychiatry|August 2, 2007
The pipeline and future of drug development in schizophreniaJ A Gray, B L Roth
The American Journal of Physiology|May 1, 1987
Altered hepatic vasopressin and alpha 1-adrenergic receptors after chronic endotoxin infusionB L Roth, J A Spitzer
Journal of Neurochemistry|June 1, 1984
Microsomal opiate receptors: characterization of smooth microsomal and synaptic membrane opiate receptorsB L Roth, C J Coscia
Peptides|January 1, 1985
The postnatal development of VIP binding sites in rat forebrain and hindbrainB L Roth, M C Beinfeld
Biochemical and Biophysical Research Communications|January 29, 1986
Phorbol esters inhibit alpha 1-adrenergic receptor-stimulated phosphoinositide hydrolysis and contraction in rat aorta: evidence for a link between vascular contraction and phosphoinositide turnoverM McMillan, B Chernow, B L Roth
Circulatory Shock|January 1, 1986
Hepatic alpha 1-adrenergic receptor alteration in a rat model of chronic sepsisM McMillan, B Chernow, B L Roth
Molecular Pharmacology|October 1, 1992
Identification of receptor domains that modify ligand binding to 5-hydroxytryptamine2 and 5-hydroxytryptamine1c serotonin receptorsM S Choudhary, S Craigo, B L Roth
Brain Research|April 1, 1982
Differential postnatal development of mu and delta opiate receptorsM Wohltmann, B L Roth, C J Coscia
Advances in Pharmacology (San Diego, Calif.)|November 5, 1997
Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptorsB L Roth, H Y Meltzer, N Khan
Molecular Pharmacology|May 1, 1993
A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptorsM S Choudhary, S Craigo, B L Roth
Pageof 12